Table 3 Univariate associations of baseline data and spectral CT parameters with responders

IOD

5.82 (3.11,7.87)

2.24 (1.76,3.80)

7.11 (5.22,8.76)

-6.490

 < 0.001

CS

1.17 (0.55,1.95)

0.37 (0.29,0.80)

1.77 (1.01,2.04)

-5.896

 < 0.001

Year

57.73 ± 12.56

56.68 ± 10.44

58.12 ± 13.30

-0.517

0.607

BLD (mm)

25.74 (20.55,30.18)

23.37 (18.83,28.41)

26.08 (21.00,31.54)

-1.422

0.155

CEA

32.91 (17.00,96.40)

21.02 (5.25,46.47)

38.84 (19.50,145.00)

-2.748

0.006

Sex

2.962

0.085

 Female

44 (42.3%)

8 (28.6%)

36 (47.4%)

 Male

60 (57.7%)

20 (71.4%)

40 (52.6%)

Primary tumor

0.586

0.444

 Rectum

53 (51.0%)

16 (57.1%)

37 (48.7%)

 Colon

51 (49.0%)

12 (42.9%)

39 (51.3%)

Sites of metastases

—

0.423*

 Liver only

83 (79.8%)

24 (85.7%)

59 (77.6%)

 Liver and extrahepatic

21 (20.2%)

4 (14.3%)

17 (22.4%)

Liver oligometastasis

0.801

0.371

 NO

71 (68.3%)

21 (75.0%)

50 (65.8%)

 YES

33 (31.7%)

7 (25.0%)

26 (34.2%0

Type of liver metastasis

3.455

0.063

 Synchronous

44 (42.3%)

16 (57.1%)

28 (36.8%)

 Metachronous

60 (57.7%)

12 (42.9%)

48 (63.2%)

Clinical T stage of the primary tumor

6.894

0.009

 T2-3

45 (43.3%)

18 (64.3%)

27 (35.5%)

 T4

59 (56.7%)

10 (35.7%)

49 (64.5%)

Clinical N stage of the primary tumor

—

0.001*

 N0-1

57 (54.8%)

23 (82.1%)

34 (44.7%)

 N2

47 (45.2%)

5 (17.9%)

42 (55.3%)

Histologic grade of the primary tumor

0.943

0.332

 Well/moderately differentiated

49 (47.12%)

11 (39.3%)

38 (50.0%)

 Others

55 (52.88%)

17 (60.7%)

38 (50.0%)

K-RAS

6.616

0.010

 Wild

49 (47.1%)

19 (67.9%)

30 (39.5%)

 Mutant

55 (52.9%)

9 (32.1%)

46 (60.5%)

Boundary

0.057

0.812

 Clear

54 (51.9%)

14 (50.0%)

40 (52.6%)

 Unclear

50 (48.1%)

14 (50.0%)

36 (47.4%)

Texture

0.042

0.838

 Homogeneous

54 (51.9%)

15 (53.6%)

39 (51.3%)

 Heterogeneous

50 (48.1%)

13 (46.4%)

37 (48.7%)

Shape

3.212

0.073

 Round

63 (60.6%)

13 (46.4%)

50 (65.8%)

 Lobulated

41 (39.4%)

15 (53.6%)

26 (34.2%)

Systemic therapy scheme

2.628

0.105

 FOLFIRI and bevacizumab

72 (69.2%)

16 (57.1%)

56 (73.7%)

 FOLFOX and bevacizumab

32 (30.8%)

12 (42.9%)

20 (26.3%)